ArticleCancer immunology, immunotherapy : CII2022

Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab.

Mathilde Bureau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.